Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726655 | 0.88 | IDH1 (0.38) | OPRM1LMNAITKTSHRNR1H4 | |
| SCHEMBL6722821 | 0.87 | NPC1 (0.41) | OPRM1LMNAITKNPC1RAB9A | |
| SCHEMBL6718318 | 0.86 | OPRM1 (0.41) | OPRM1LMNANPC1RAB9AP2RX7 | |
| SCHEMBL6722876 | 0.85 | ALDH1A1 (0.39) | OPRM1LMNAITKNPC1RAB9A | |
| SCHEMBL6714072 | 0.85 | NR1H4 (0.41) | OPRM1LMNAITKNPC1P2RX7 | |
| SCHEMBL6714288 | 0.79 | HPGD (0.39) | ITKNPC1RAB9ATSHRNR1H4 | |
| SCHEMBL6718458 | 0.79 | ALDH1A1 (0.42) | OPRM1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6719441 | 0.78 | OPRM1 (0.38) | OPRM1LMNANPC1RAB9AP2RX7 | |
| SCHEMBL6717391 | 0.77 | LMNA (0.38) | OPRM1LMNANPC1RAB9AMEN1 | |
| SCHEMBL6723392 | 0.76 | SMN1; SMN2 (0.41) | ITKNPC1RAB9ANR1H4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | OPRM1 719/4885LMNA 3809/4885ITK 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.